NCT04979052View on ClinicalTrials.gov

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Candidemia
Interventions
DRUG

Interferon Gamma-1B

100 microgram per day, three times a week, subcutaneous. The duration of the treatment is twelve days or until hospital discharge.

Trial Locations (6)

1005

RECRUITING

Centre Hospitalier Universitaire Vaudois, Lausanne

11528

RECRUITING

Hellenic Institute for the Study of Sepsis (HISS), Athens

27708

RECRUITING

Duke University, Durham

60590

RECRUITING

Klinikum Der Johann Wolfgang Von Goethe Universitaet, Frankfurt am Main

400348

RECRUITING

Universitatea de Medicina si Farmacie luliu Hatieganu, Cluj-Napoca

6525 GA

RECRUITING

Radboudumc, Nijmegen

All Listed Sponsors
collaborator

Horizon 2020 - European Commission

OTHER

lead

Radboud University Medical Center

OTHER